Dual-Stimuli-Responsive Gut Microbiota-Targeting Nitidine Chloride-CS/PT-NPs Improved Metabolic Status in NAFLD
Jianmei Lu,Yongzhu Zeng,Huashuai Zhong,Wei Guo,Yuyan Zhang,Wanting Mai,Yucui Qin,Xiaodan Su,Bo Zhang,Weisen Wu,Yu Zhu,Qiujie Huang,Yong Ye
DOI: https://doi.org/10.2147/ijn.s452194
IF: 7.033
2024-03-09
International Journal of Nanomedicine
Abstract:Jianmei Lu, 1, 2, &ast Yongzhu Zeng, 1, &ast Huashuai Zhong, 1 Wei Guo, 1 Yuyan Zhang, 1 Wanting Mai, 3 Yucui Qin, 4 Xiaodan Su, 3 Bo Zhang, 5 Weisen Wu, 1 Yu Zhu, 1 Qiujie Huang, 6 Yong Ye 1, 7– 9 1 Department of Pharmacy, Guangxi Medical University, Nanning, People's Republic of China; 2 The Second Nanning People's Hospital, Nanning, People's Republic of China; 3 The Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China; 4 Maternity and Child Health Care of Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China; 5 Scientific Research Center, Guilin Medical University, Guilin, People's Republic of China; 6 Department of Pharmacy, Guangxi University of Traditional Chinese Medicine, Nanning, People's Republic of China; 7 Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Nanning, People's Republic of China; 8 Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Nanning, People's Republic of China; 9 Key Laboratory of Micro-Nanoscale Bioanalysis and Drug Screening of Guangxi Education Department, Nanning, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qiujie Huang, Department of Pharmacy, Guangxi University of Traditional Chinese Medicine, Nanning, People's Republic of China, Email Yong Ye, Department of Pharmacy, Guangxi Medical University, Nanning, People's Republic of China, Email Background and Purpose: Nitidine chloride (NC) is a botanical drug renowned for its potent anti-inflammatory, antimalarial, and hepatocellular carcinoma-inhibiting properties; however, its limited solubility poses challenges to its development and application. To address this issue, we have devised a colon-targeted delivery system (NC-CS/PT-NPs) aimed at modulating the dysbiosis of the gut microbiota by augmenting the interaction between NC and the intestinal microbiota, thereby exerting an effect against nonalcoholic fatty liver disease. Methods: The NC-CS/PT-NPs were synthesized using the ion gel method. Subsequently, the particle size distribution, morphology, drug loading efficiency, and release behavior of the NC-CS/PT-NPs were characterized. Furthermore, the impact of NC-CS/PT-NPs on non-alcoholic fatty liver disease (NAFLD) induced by a high-fat diet (HFD) in mice was investigated through serum biochemical analysis, ELISA, and histochemical staining. Additionally, the influence of NC-CS/PT-NPs on intestinal microbiota was analyzed using 16S rDNA gene sequencing. Results: The nanoparticles prepared in this study have an average particle size of (255.9± 5.10) nm, with an encapsulation rate of (72.83± 2.13) % and a drug loading of (4.65± 0.44) %. In vitro release experiments demonstrated that the cumulative release rate in the stomach and small intestine was lower than 22.0%, while it reached 66.75% in the colon. In vivo experiments conducted on HFD-induced NAFLD mice showed that treatment with NC-CS/PT-NPs inhibited weight gain, decreased serum aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and lipid levels, improved liver and intestinal inflammation, and altered the diversity of gut microbiota in mice. Conclusion: This study provides new evidence for the treatment of NAFLD through the regulation of gut microbiota using active ingredients from traditional Chinese medicine. Keywords: nanoparticles, colonic targeting, metabolic disorders, gut microbiota Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease throughout the world. 1,2 It encompasses a spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which is a more aggressive form of the disease that can progress to liver fibrosis, cirrhosis, and life-threatening complications. 3 The global incidence of NAFLD has been steadily increasing, with a growth rate of 0.7% per year between 1990 and 2019. In 2019, the prevalence rate reached approximately 37%. Notably, North and South America had the highest prevalence rates at 35%, while Asia and Europe exhibited a prevalence rate of 28%. 4 China has particularly high rates of NAFLD, with an overall prevalence rate of 29.6% from 1999 to 2018. This makes China the country with the highest prevalence, incidence, and annual NAFLD-related mortality rate in Asia. It is projected that by 2030, China will experience the largest increase in NAFLD prevalence globally, leading to a significant rise in the economic burden -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology